Goldman Urology Clinic has recently surpassed 6,000 cumulative surgeries for benign prostatic hyperplasia (BPH), demonstrating strong clinical capability in the treatment of prostate enlargement. The clinic attributes this achievement to its approach of carefully analyzing each patient’s condition and selecting the most appropriate surgical technique.
Benign prostatic hyperplasia is commonly seen in middle-aged and older men. As the prostate enlarges excessively, it compresses the urethra and causes lower urinary tract symptoms such as frequent urination, nocturia, a sensation of incomplete bladder emptying, and delayed urination. In the early stages, symptoms can often be controlled with medication. However, when the response to medication decreases or symptoms repeatedly worsen, surgical treatment may become necessary. At this stage, it is important to consider not only the size and shape of the prostate but also the patient’s symptoms, possible complications, underlying chronic diseases, anesthesia considerations, and recovery plans in order to select the most appropriate procedure.
Based on these principles, Goldman Urology Clinic has focused on introducing advanced surgical techniques and refining its clinical protocols. These include Rezūm therapy, which injects high-temperature steam to induce necrosis and shrink enlarged prostate tissue; Aquablation, a robotic waterjet procedure that uses high-pressure water guided by an AI-based system to precisely remove prostate tissue without thermal damage; and Holmium Laser Enucleation of the Prostate (HoLEP), which removes enlarged prostate tissue using a holmium laser.
The clinic also offers additional treatment options such as the iTind device, which expands the prostatic urethra, and the UroLift system, which reduces the burden associated with surgical tissue removal. By offering a broad range of treatment methods, the clinic has developed a personalized treatment strategy tailored to each patient’s prostate size, anatomical structure, and symptom severity.
In addition, Goldman Urology Clinic continues to conduct research on benign prostatic hyperplasia based on more than two million accumulated clinical cases collected over more than 20 years. These research efforts have translated into measurable clinical outcomes and positive evaluations in real-world practice. For example, the clinic has presented research findings related to robotic waterjet surgery at academic conferences and has continuously evaluated and refined the safety and effectiveness of new surgical techniques in clinical settings.
Dr. Lee Chang-gi, CEO of Goldman Urology Clinic, explained that the results of BPH surgery inevitably depend on factors such as the experience of the medical team, the accuracy of preoperative evaluation, and the quality of postoperative care systems. He noted that physicians across all branches of Goldman Urology Clinic regularly share clinical data and collaboratively develop treatment protocols, improving both consistency and safety in patient care.
He also emphasized that benign prostatic hyperplasia affects patients differently. Because each patient experiences different symptoms and may have different accompanying conditions or recovery plans, relying on a single treatment method as the standard solution is not appropriate. Instead, he explained that the key principle is to recommend the most suitable procedure at the appropriate time according to the patient’s individual condition and needs.